ABSTRACT
Burden of stroke differs by region, which could be attributed to differences in comorbid conditions and ethnicity. Genomewide variation acts as a proxy marker for ethnicity, and comorbid conditions. We present an integrated approach to understand this variation by considering prevalence and mortality rates of stroke and its comorbid risk for 204 countries from 2009 to 2019, and GWAS risk variant for all these conditions. Global and regional trend analysis of rates using linear regression, correlation and proportion analysis, signify ethnogeographic differences. Interestingly, the comorbid conditions that act as risk drivers for stroke differed by regions, with more of metabolic risk in America and Europe, in contrast to high SBP in Asian and African regions. GWAS risk loci of stroke and its comorbid conditions indicate distinct population stratification for each of these conditions, signifying for population specific risk. Unique and shared genetic risk variants for stroke, and its comorbid and followed up with ethnic specific variation can help in determining regional risk drivers for stroke. Unique ethnic specific risk variants and their distinct patterns of Linkage Disequilibrium further uncover the drivers for phenotypic variation. Therefore, identifying population and comorbidity specific risk variants might help in defining the threshold for risk, and aid in developing population specific prevention strategies for stroke.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
RS acknowledges the support of Kerala State Council for Science, Technology and Environment, (KSCSTE) for providing the research fellowship. RS and ASN acknowledge the SIUCEB support at the Department of Computational Biology and Bioinformatics, University of Kerala for providing the necessary facilities to carry out the work. MB acknowledges the Dept. of Biotechnology for providing intra-mural support to carry out the work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The datasets analyzed during the current study are available in the GBD database, at https://vizhub.healthdata.org/gbd-results/?params=gbd-api-2019-permalink/fe8b05e8222bcf3ec3af555762006f2a
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The revision is only about expanding the acronyms and supplementary files attached to the figures
Data Availability
The datasets analysed during the current study are available in the GBD database, at https://vizhub.healthdata.org/gbd-results/?params=gbd-api-2019-permalink/fe8b05e8222bcf3ec3af555762006f2a. All other materials including computer code will be available upon request. Please contact corresponding author for the same.
